INTRODUCTION
Since 1997, the National Birth Defects Prevention Network (NBDPN), in collaboration with the Centers for Disease Control and Prevention (CDC), has published data on major birth defects affecting the central nervous, eye, ear, cardiovascular, orofacial, gastrointestinal, genitourinary, and musculoskeletal systems, as well as trisomies, amniotic bands, and fetal alcohol syndrome, from population-based birth defects surveillance programs in the United States. Annually, the NBDPN Data Committee issues a data request to population-based birth defects programs for data on 47 major birth defects; the specific defects with accompanying diagnostic codes are detailed in Appendix 1 on page 10. This year's report containing data from 41 population-based birth defects surveillance programs for births occurring from January 1, 2005, through December 31, 2009, is available as a supplement on pages. The data are presented by racial/ethnic groups for all defects and additionally by maternal age for trisomies 13, 18, and 21.
To calculate prevalence, programs were also asked to provide the number of total live births and male live births for each calendar year submitted. The standard method for calculating birth defects prevalence is to divide the number of cases (birth defect for any pregnancy outcome) by total live births for the catchment area and then multiply by 10,000 to obtain the prevalence per 10,000 live births; Mason et al. (2005) provide further detail and rationale for this approach. This methodology is used for all defects except hypospadias, which is calculated using a denominator of total male live births. An attempt was made to standardize both the submitted data and presentation of state surveillance data, however, differences in the way programs collect and report birth defects data are listed in the footnotes of the accompanying tables and may be referenced in the program directories on pages S121-S169 (online). Some programs were able to only provide data for selected years, were unable to report counts and prevalence by race/ethnicity, or were unable to provide data for each specific defect requested due to differences in the coding systems (i.e., International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] vs CDC/British Pediatric Association [BPA] ) Classification of Diseases used to classify birth defects.
Critical Congenital Heart Defects Targeted for Pulse Oximetry Screening
This year's data report includes several enhancements to address the interest in pulse oximetry screening of newborns for critical congenital heart defects (CCHDs). Con- genital heart defects (CHDs) occur in an estimated 1 in 110 births in the United States (Reller et al., 2008) and approximately 25% of CHDs are considered CCHDs, defined as requiring surgery or catheter intervention within the first year of life (Mahle et al., 2009) . Children with CCHDs are at risk for death or disability if the defect is not detected shortly after birth (Mahle et al., 2009 Newborns and Children (2011) named seven CCHDs as primary targets for screening: common truncus, d-transposition of the great arteries, tetralogy of Fallot, pulmonary valve atresia, tricuspid valve atresia, hypoplastic left heart syndrome, and total anomalous pulmonary venous return (Mahle et al., 2009; Kemper et al., 2011) . Other CCHDs may also be detected using pulse oximetry screening, but because they may not consistently have hypoxemia at or soon after birth, their identification would be variable and incomplete. The following CCHDs are considered secondary targets of pulse oximetry screening: coarctation of the aorta, double outlet right ventricle, Ebstein anomaly, interrupted aortic arch, single ventricle, severe aortic stenosis and severe pulmonary stenosis (Mahle et al., 2009) .
The implementation of pulse oximetry screening for CCHDs is currently underway in a few states, with more considering legislation and implementation (Olney and Botto, 2012) . Surveillance case definitions, including both ICD-9-CM and CDC/BPA diagnostic codes, for each of the seven primary CCHD targets of pulse oximetry screening are presented in Appendix 2. In using these case definitions, it is important to consider as a potential limitation the coding system's ability to capture cases of CCHDs. Three of the seven conditions ('pulmonary valve atresia and stenosis', 'tricuspid valve atresia and stenosis', and 'transposition of the great arteries') include both broad codes to capture all possible cases that are generally collected for surveillance purpose and more refined codes that are targeted for newborn screening of CCHDs using pulse oximetry. For example, the surveillance category of 'tricuspid valve atresia and stenosis' encompasses both tricuspid valve atresia (one of the seven targeted CCHDs) as well as milder cases of tricuspid stenosis. Programs that are able to use more refined codes provided data separately for pulmonary valve atresia, tricuspid valve atresia, and d-transposition of the great arteries. tion-based birth defects surveillance programs in the United States. Because pulse oximetry screening occurs in newborns, data presented in Table 1 include live births only; accompanying state-specific data tables available at S1-S120 include cases resulting from any pregnancy outcome (i.e., live births, stillbirths, and/or pregnancy terminations). For the three CHD diagnoses mentioned above, data are presented for both the broad surveillance category and the stricter definition for pulse oximetry screening. Figure 1 presents the data from Table 1 graphically for each CCHD, grouped by the program's primary case finding approach (active or passive). Three 'central tendency statistics' are presented: (1) mean prevalence defined as the arithmetic average of the individual program prevalences; (2) median prevalence representing the middle value of the individual program prevalences; and (3) pooled prevalence calculated by dividing the total number of cases across programs by total number of combined live births.
CCHD Data Presentation

DISCUSSION
Variability in the observed prevalence of CCHDs across states could be due to true differences in prevalence; however, other reasons may account for the variability. Some programs could only provide data for select years. Others were unable to provide data on specific defects, because the conditions are not part of their program case inclusion or due to limitations in the coding systems. Another consideration for variability in the reported prevalence includes pregnancy termination practice for prenatally diagnosed cases. Pregnancy terminations likely vary among states based on cultural differences, race/ethnicity, and other factors (Peller et al., 2004) . Higher birth prevalence in a given state may reflect fewer pregnancy terminations of prenatally diagnosed cases. Table 1 indicates whether the program primarily used an active or passive case finding approach to collect the data. Case finding methodology can influence the magnitude of the prevalence estimates (Parker et al., 2010) . Programs with active case finding generally have the ability to use a more refined case classification than programs with passive case finding that rely on ICD-9-CM codes alone; Strickland et al. (2008) demonstrated that compared to clinical nomenclature, ICD-9-CM coding can have relatively low sensitivity and high false-positive fraction for some CHDs. The lack of refinement in the coding leads to the inability to distinguish specific CCHDs (e.g., one code for tricuspid valve atresia and stenosis instead of separate codes for each subtype). Programs can improve their data quality through case confirmation and expert case review. In addition, inclusion of pediatric cardiology centers as a data source can improve and refine case ascertainment (Bedard et al., 2012) . Given that individual CCHDs are rare, missing or over-reporting even a few cases may strongly affect the reported prevalence. Figure 1 shows that although prevalence among the programs can vary greatly, the mean prevalences are similar for some CCHDs (e.g., pulmonary valve atresia).
CONCLUSION
As CCHD screening is being implemented across the United States, population-based birth defects surveillance programs can provide useful data to assist with the evaluation of CCHD screening by providing the ongoing and timely evidence to assess the sensitivity, specificity, and positive predictive value (Olney and Botto, 2012) . The information gathered by birth defects surveillance programs could also provide an initial basis to assess outcomes, beginning from infant mortality and expanding, depending on a program's ability and resources, to include ultimately an evaluation of the cost effectiveness of CCHD screening. Appendix Table 2 Case Definition for the Seven Primary Targeted Critical Congenital Heart Defects Common Truncus (Truncus Arteriosus or TA)
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Description
Failure of separation of the aorta and the pulmonary artery, resulting in a single common arterial trunk carrying blood from the heart to both the body and lungs.
Inclusions Common truncus Truncus arteriosus (TA) Persistent truncus arteriosus Exclusions
Aorto-pulmonary window ICD-9-CM codes 745.0 CDC/BPA codes 745.00 (remove 745.01, aortic septal defect including aorto-pulmonary window)
Diagnostic methods
Truncus arteriosus is conclusively diagnosed only through direct visualization of the heart by cardiac imaging (typically echocardiography but also MRI), catheterization, surgery, or autopsy. A clinical diagnosis is considered insufficient to make the diagnosis.
Prenatal diagnoses not confirmed postnatally
These conditions may be included as cases when only diagnosed prenatally with some degree of certainty by a pediatric cardiologist through fetal echocardiography. Live-born children who survive should always have confirmation of the defect postnatally.
Additional information:
A ventricular septal defect is often present in association with truncus defects and should be coded separately. Truncus arteriosus is one of several abnormalities of the outflow tract of the heart known as conotruncal defects. Some infants (1 in 5 to 1 in 3) with these defects have an interstitial deletion on the short arm of chromosome 22 (22q11.2 deletion). This deletion is reliably diagnosed by fluorescent in situ hybridization (FISH) or microarray technology and may be missed by routine karyotype analysis. 
Diagnostic methods
d-TGA is conclusively diagnosed through direct visualization of the heart by cardiac echo (echocardiography), catheterization, surgery, or autopsy. Case Definition for the Seven Primary Targeted Critical Congenital Heart Defects (Continued)
Prenatal diagnoses not confirmed postnatally These conditions may be included as cases when only diagnosed prenatally with some degree of certainty by a pediatric cardiologist through fetal echocardiography. Live-born children who survive should always have confirmation of the defect postnatally. Additional information: d-TGA is a defect in which the right ventricle connects to the aorta and the left ventricle connects to the pulmonary artery (ventriculoarterial discordance). An associated communication between the pulmonary and systemic circulations may be present, such as a ventricular septal defect (incomplete TGA). If a VSD is not present (intact ventricular septum) it is complete TGA. If the coding system does not include unique codes to differentiate TGA with and w/o a VSD (complete vs. incomplete), the VSD should be coded separately when present. If a communication (e.g., ASD) is created during catheterization or surgery, the ASD is not coded as a defect. DORV is a distinct defect coded within this category. DORV can occur with normally or malposed great vessels. Strictly speaking, the great arteries in DORV cannot be transposed, and are malposed, although ICD-9 coding is limited. If a coding system (e.g., CDC/ BPA), can distinguish these phenotypes, only the DORV with transposed vessels is included in the larger transposition category or the CCHD subcategory. If codes cannot distinguish phenotypes, all DORVs are included in the transposition category, but not CCHD subcategory. L-TGA (corrected transposition) is a defect in which the right atrium connects to anatomic left ventricle (atrio-ventricular discordance) and this ventricle connects to the pulmonary artery (ventriculo-arterial discordance). Because oxygen-poor blood goes to the lungs and oxygen-rich blood goes to the body, circulation is normal (corrected transposition) as long as there are no other defects. L-TGA is included in the broader transposition category for surveillance, but excluded from CCHD subcategory because it is not considered critical. Transposition of the great arteries is one of several abnormalities of the outflow tract of the heart known as conotruncal defects. Very few infants with these defects have an interstitial deletion on the short arm of chromosome 22 (22q11.2 deletion). This deletion is reliably diagnosed by fluorescent in situ hybridization (FISH) or microarray technology and may be missed by routine karyotype analysis.
Tetralogy of Fallot (TOF) Description
The simultaneous presence of a VSD, pulmonic and subpulmonic stenosis, a malpositioned aorta that overrides the ventricular septum, and right ventricular hypertrophy. 
Diagnostic methods
While Tetralogy of Fallot may be suspected by clinical presentation, it may be conclusively diagnosed only through direct visualization of the heart by cardiac echo (echocardiography), catheterization, surgery, or autopsy.
Prenatal diagnoses not confirmed postnatally
These conditions may be included as cases when only diagnosed prenatally with some degree of certainty by a pediatric cardiologist through fetal echocardiography. Live-born children who survive should always have confirmation of the defect postnatally. Additional information: Tetralogy of Fallot is one of several abnormalities of the outflow tract of the heart known as conotruncal defects. Some infants (approximately 1 in 7) with this defect have an interstitial deletion on the short arm of chromosome 22 (22q11.2 deletion). This deletion is reliably diagnosed by fluorescent in situ hybridization (FISH) or microarray technology and may be missed by routine karyotype analysis. Tetralogy of Fallot is on a spectrum with other defects having important physiologic and coding differences among systems as seen here in the 
Diagnostic methods
Although pulmonary valve atresia or stenosis may be suspected by clinical presentation, it may be conclusively diagnosed only through direct visualization of the heart by cardiac echo (echocardiography), catheterization, surgery, or autopsy.
Prenatal diagnoses not confirmed postnatally
Although these conditions may be identified by prenatal ultrasound, they should not be included in surveillance data w/o postnatal confirmation. In addition, the absence of pulmonary valve atresia or stenosis on prenatal ultrasound does not necessarily mean that it will not be diagnosed after delivery. Additional information: These defects have important physiologic and coding differences among systems as seen here in the Table, 
Diagnostic methods
Although tricuspid valve atresia or stenosis may be suspected by clinical presentation, it may be conclusively diagnosed only through direct visualization of the heart by cardiac echo (echocardiography), catheterization, surgery, or autopsy.
Prenatal diagnoses not confirmed postnatally
Although these conditions may be identified by prenatal ultrasound, they should not be included in surveillance data w/o postnatal confirmation. In addition, the absence of tricuspid valve atresia or stenosis on prenatal ultrasound does not necessarily mean that it will not be diagnosed after delivery.
